A recent Neurology digest,
as sent to subscribers

Study Type: Cross-sectional case-control neuroimaging study (pooled analysis of three independent fMRI datasets)

Key Question: Does altered dynamic functional network integration, particularly involving the cerebellar vermis, underlie the pathophysiology of episodic cluster headache (CH)?

Key Findings:

• CH patients (n=100) showed significantly reduced entropy in the cerebellar vermis (β = -0.493, pFDR = 3.02×10⁻⁶) and cerebellar network versus 116 controls, indicating loss of dynamic flexibility.
• Longer disease duration correlated with greater vermal entropy reduction (r = -0.390, pFDR = 0.004).
• Motif analysis showed increased forked triads (vermis rigidly hub-linking sensorimotor, visual, default-mode, cerebellar nodes) but decreased diverse triads connecting vermis to cognitive-control and default-mode networks (all pFDR <0.05).

Clinical Relevance: These findings implicate the cerebellar vermis as a disease-duration-dependent hub with paradoxically rigid connectivity in CH, supporting its candidacy as a neuromodulation target for refractory cases seen in UK headache clinics.

Limitations: Cross-sectional design precludes causal inference regarding whether vermal network changes drive or result from chronic CH.

Study Type: Multicentre diagnostic biomarker cohort study (retrospective, cross-sectional/prognostic analysis)

Key Question: Can CSF GDF15 (alone or with CEACAM6) accurately diagnose leptomeningeal metastasis (LM) and predict prognosis in lung adenocarcinoma (LUAD) and breast cancer (BC)?

Key Findings:

• CSF GDF15 was elevated >25-fold in LUAD LM vs Non-LM, with excellent discrimination (AUC 0.912–0.975) across LUAD Non-LM, neurological controls, parenchymal brain metastasis, and intracranial tumours.
• CEACAM6 showed similarly strong performance (AUC 0.956–0.970) distinguishing LUAD LM from brain metastasis/intracranial tumours; combined GDF15+CEACAM6 outperformed either marker alone in both LUAD and BC LM.
• High CSF GDF15 was associated with shorter overall survival in LUAD LM patients.

Clinical Relevance: GDF15 (± CEACAM6) offers a promising, minimally invasive CSF biomarker to improve early LM diagnosis and risk stratification, addressing a key unmet need in NHS neuro-oncology pathways where cytology sensitivity is limited.

Limitations: Retrospective design with tumour-type-specific cohorts limits generalisability and requires prospective validation before clinical adoption.

Study Type: Post hoc analysis of an RCT (LASTE trial)

Key Question: Does thrombectomy improve outcomes over medical management alone in large-core anterior circulation stroke (ASPECTS 0–5) diagnosed at a primary stroke centre prior to transfer for endovascular therapy?

Key Findings:

• Thrombectomy plus medical management improved 90-day functional outcome versus medical management alone (generalised OR 1.71; 95% CI 1.21–2.41; p=0.002), with no heterogeneity by ASPECTS subgroup (including 0–2 vs 3–5).
• Mortality was numerically lower with thrombectomy (RR 0.73; 95% CI 0.50–1.05); symptomatic intracranial haemorrhage was numerically higher (RR 1.85; 95% CI 0.64–5.26).
• Cohort reflected real-world transfer delays (median last-seen-well-to-PSC imaging 120 minutes), with over half having ASPECTS 0–2.

Clinical Relevance: Supports transfer pathways to comprehensive stroke centres for thrombectomy even in very large-core strokes (ASPECTS 0–2) diagnosed at PSCs, relevant to UK hub-and-spoke stroke networks optimising drip-and-ship protocols.

Limitations: Subgroup/post hoc analysis with reduced power, particularly for safety outcomes (wide CIs for haemorrhage and mortality).

Study Type: Cross-sectional cohort study

Key Question: Does APOE genotype influence sleep macro- and microarchitecture in middle-aged to older adults, potentially linking sleep changes to Alzheimer's disease risk?

Key Findings:

• Sleep macroarchitecture (sleep stage percentages, wake after sleep onset) did not differ meaningfully by APOE genotype.
• ε4 homozygotes showed reduced spindle power (β = -2.14, p = 0.02) and a dose-dependent decline in spindle frequency at peak power across ε4 dose.
• ORP and arousal index decreased in a dose-response manner with increasing ε4 count (ORP p < 0.01 both groups), with ORP differences widening with age; associations were independent of sex, race, cognition, pTau181, and Aβ42:40 ratio.

Clinical Relevance: These findings suggest subtle EEG microarchitectural changes—rather than gross sleep stage disruption—may represent an early, genotype-linked marker of AD vulnerability, relevant to UK memory clinics considering sleep-based biomarkers in at-risk populations.

Limitations: Cross-sectional design precludes causal inference regarding sleep microarchitecture changes and AD pathogenesis.

Study Type: Multi-cohort genetic association study (retrospective analysis across four independent cohorts)

Key Question: Do the cognitive versus non-cognitive genetic components of educational attainment differentially influence risk of Alzheimer's disease diagnosis and pathology?

Key Findings:

• Higher cognitive-EA polygenic score was significantly associated with lower AD diagnosis risk across all four cohorts (BioHermes-1, ADNI, ROSMAP, BDR) and with lower Braak stage in ROSMAP and BDR.
• Non-cognitive EA polygenic score showed no significant association with AD diagnosis, amyloid PET status, plasma neurodegenerative biomarkers, or CERAD scores.
• Findings implicate a genetically-mediated "brain maintenance" mechanism linked specifically to intelligence-related genetic architecture, not to social/behavioural aspects of educational attainment.

Clinical Relevance: For UK dementia prevention strategy, this suggests policies aimed purely at increasing years of schooling may have limited impact on AD incidence, whereas interventions or biomarkers targeting cognitive-reserve pathways may be more fruitful for risk stratification and prevention research.

Limitations: Polygenic scores derived largely from European-ancestry GWAS limit generalisability, and cross-sectional/postmortem designs cannot establish causal mechanisms of resilience.

Study Type: Cross-sectional imaging cohort study (retrospective comparative analysis)

Key Question: Does quantitative NCCT-derived percent net water uptake (%NWU) detect early ischemic edema more sensitively than FLAIR-MRI hyperintensity, using DWI as reference standard?

Key Findings:

• Among 53 DWI-positive hyperacute stroke patients stratified into 4 edema profiles, %NWU rose progressively and near-linearly from 1.4% to 13.6% across stages within 4.5 hours (all pairwise p<0.012), while rFLAIR only increased significantly in the latest (sulcal effacement) stage.
• %NWU and rFLAIR were uncorrelated (R²=0.02, p=0.48), and rADC did not differ between groups (p=0.21), indicating %NWU captures an earlier, distinct physiological process.

Clinical Relevance: In CT-first UK stroke pathways, %NWU could serve as a rapid, quantitative early edema biomarker for hyperacute triage and risk stratification without requiring MRI access.

Limitations: Small retrospective single/multi-timepoint sample with visual profile categorisation, requiring prospective validation before clinical adoption.

Study Type: Cross-sectional genetic association study

Key Question: Does genetic ancestry explain previously reported differences in MS severity between ethnic groups in the UK?

Key Findings:

• Among 816 pwMS (South Asian 31.9%, African 20.0%, European 38.7%, other 9.4%), neither South Asian nor African ancestry was consistently associated with higher ARMSS-based disability compared with European ancestry.
• No genetic variants reached genome-wide significance for association with MS severity.

Clinical Relevance: Suggests that previously observed ethnic disparities in MS outcomes in UK populations are unlikely to be driven by genetic ancestry, pointing instead towards socioeconomic, healthcare access, or environmental factors—relevant to NHS efforts to address health inequalities in MS care.

Limitations: Cross-sectional design with self-reported severity measures limits causal inference and may not capture longitudinal disease trajectories.

Study Type: Narrative review

Key Question: How does gut wall dysfunction—spanning intestinal barrier integrity, enteric nervous system (ENS), and mucosal immunity—contribute to the pathogenesis of MS and autoimmune neurological diseases?

Key Findings:

• Proposes intestinal barrier disruption and mucosal immune activation as upstream drivers of CNS autoimmunity in MS, linking microbiome dysregulation to neuroinflammatory priming.
• Identifies the ENS itself as a novel, underrecognised target of autoimmune injury in certain antibody- and T cell-mediated neurological diseases, rather than solely a bystander in gut-brain signalling.
• Offers a unifying conceptual framework positioning the gut as both an initiating immune site and a direct target organ across a spectrum of neuroimmunological conditions.

Clinical Relevance: This reframes gastrointestinal symptoms and gut-directed biomarkers/therapeutics as potentially central—not incidental—to MS and autoimmune neurology management, relevant to emerging microbiome-based and ENS-targeted interventions in UK practice.

Limitations: As a narrative review, it synthesises conceptual and preclinical evidence rather than presenting new primary or systematically appraised clinical data.